
==== Front
JMIR Res Protoc
JMIR Res Protoc
ResProt
JMIR Research Protocols
1929-0748
JMIR Publications Toronto, Canada

v13i1e60828
39163116
10.2196/60828
Protocol
Protocol
Effectiveness of Aerobic Training for Adverse Symptoms Related to Chemotherapy During Treatment: Protocol for a Randomized Controlled Trial With Cost-Effectiveness Assessment
Leung Tiffany
Selles William de Lima MSc 1https://orcid.org/0000-0002-9495-108X

Miyamoto Gisela Cristiane PhD 1https://orcid.org/0000-0002-6826-4278

Santos Elinaldo da Conceição PhD 2https://orcid.org/0000-0002-4039-2980

Carmo Cibelle Regina Lima PT 1https://orcid.org/0009-0003-4750-154X

Moura Giovanni Marini PT 1https://orcid.org/0009-0000-5664-097X

Santos Giovanna Marques Frascoli PT 1https://orcid.org/0009-0004-3080-6803

Lopes Giovanna dos Santos PT 1https://orcid.org/0009-0005-0019-1462

Silva Diego Wisnieski PT 1https://orcid.org/0009-0005-1607-9942

Pereira Leticia Jeremias Ferreira PT 1https://orcid.org/0009-0006-5582-7330

Lunardi Adriana Claudia PhD https://orcid.org/0000-0002-6133-3816
13Master's and Doctorate Program Universidade Cidade de São Paulo 475th Cesareo Galeno Street Sao Paulo, 03071-000 Brazil 55 11999774639 adrianalunardi@hotmail.com

1 Master's and Doctorate Program Universidade Cidade de São Paulo Sao Paulo Brazil
2 Department of Biological and Health Sciences Universidade Federal do Amapá Macapá Brazil
3 Department of Physical Therapy University of Sao Paulo Sao Paulo Brazil
Corresponding Author: Adriana Claudia Lunardi adrianalunardi@hotmail.com
2024
20 8 2024
13 e6082823 5 2024
19 6 2024
26 6 2024
9 7 2024
©William de Lima Selles, Gisela Cristiane Miyamoto, Elinaldo da Conceição Santos, Cibelle Regina Lima Carmo, Giovanni Marini Moura, Giovanna Marques Frascoli Santos, Giovanna dos Santos Lopes, Diego Wisnieski Silva, Leticia Jeremias Ferreira Pereira, Adriana Claudia Lunardi. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 20.08.2024.
2024
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.

Background

One strategy to prevent adverse effects resulting from chemotherapy treatment is to perform physical exercises during treatment. However, there is still no consensus on the best type and intensity of exercise, nor when it should be started. Most studies have been carried out in patients with breast cancer, usually a few weeks after starting chemotherapy, on an outpatient basis 2 to 3 times a week. The main differences in our study are that we carried out physical training in hospitalized patients undergoing a cycle of chemotherapy for cancer treatment and that this training was carried out 5 times a week and was not restricted to a specific type of cancer.

Objective

We aimed to evaluate the effects of aerobic training on symptoms related to chemotherapy (nausea, vomiting, asthenia, and sensation of weakness), fatigue, mobility, clinical complications, and length of hospital stay of patients during the drug treatment cycle. We also evaluated patient satisfaction with the proposed intervention, the adverse effects of aerobics training, and the cost-effectiveness of this intervention.

Methods

This is a controlled and randomized trial with blinded evaluation that will include 94 hospitalized patients with cancer for 1 or more cycles of chemotherapy. The intervention group will perform aerobic training during a cycle of chemotherapy. The control group will receive a booklet with guidelines for staying active during the hospitalization period. The groups will be compared using a linear mixed model for fatigue, mobility, and chemotherapy-related symptoms before and after the intervention. The length of hospital stay will also be compared between groups using Kaplan-Meier survival analysis. The incidence of complications will be compared using the χ2 test. Cost-effectiveness and cost-utility analyses will be performed for the impact of exercise and quality-adjusted life years with the EQ-5D-3L-21 quality of life trials. The implementation variables (acceptability, suitability, and feasibility) will be evaluated by frequencies.

Results

The clinical trial registration was approved in March 2023. Recruitment and data collection for the trial are ongoing, and the results of this study are likely to be published in late 2025.

Conclusions

Chemotherapy has side effects that negatively impact the quality of life of patients with cancer. Aerobic exercise can reduce these side effects in a simple and inexpensive way. The field of work of physical therapists could be expanded to oncology if the intervention works.

Trial Registration

Registro Brasileiro de Ensaios Clínicos RBR-6b4zwx3; https://tinyurl.com/39c4c7wz

International Registered Report Identifier (IRRID)

DERR1-10.2196/60828

cancer
exercise
chemotherapy
physical therapy
cost benefit analyses
economic evaluation
ext-peer-rev The proposal for this study was externally peer-reviewed by the Pró-Reitoria de Pós-Graduação, Pesquisa e Extensão (PRPGPE) - Universidade Cidade de São Paulo (UNICID) - São Paulo Research Foundation (FAPESP) (Brazil). See the Multimedia Appendix for the peer-review report;
==== Body
pmcIntroduction

Cancer is already the biggest public health problem in the world. In Brazil, the estimate for the 2023-2025 period is that there will be 704,000 new cases of cancer per year (excluding cases of nonmelanoma skin cancer) [1]. One of the main forms of treatment for cancer is chemotherapy, which consists of a systemic treatment in which a drug is used to interfere with cell proliferation, targeting its DNA or RNA and its metabolism [2]. The costs of cancer treatment in the United States already reach US $158 billion per year [3], and in Brazil, they exceed R $3.5 billion (US $700 million) [4]. The application of these resources requires health care staff, medications used directly and indirectly in treatment, equipment, and hospitalization days.

Treatment with chemotherapy involves a series of side effects, including nausea, vomiting, diarrhea, and febrile neutropenia, which are treated with supplementary medications. These adverse effects have a major impact on patients’ lives, as well as on adherence and compliance with the recommended dose of treatment, and they are also associated with an increase in the rate of hospitalization. At least one-third of women undergoing adjuvant chemotherapy treatment for breast cancer are unable to complete the prescribed dose of treatment due to adverse effects, thus compromising the prognosis of the disease [5].

Physical exercise in patients with cancer during chemotherapy has been tested in randomized trials [5-11] and appears to improve physical function, fatigue, symptom burden, and the quality of life of patients, in addition to allowing the nonreduction of chemotherapy doses. However, most studies have been carried out on an outpatient basis, involved patients with breast cancer, used 3 weekly exercise sessions, and evaluated fatigue as the primary outcome. There are still no clinical trials testing the effect of exercise in a hospital environment with daily sessions (Monday to Friday) carried out during the chemotherapy cycle.

Therefore, our objective is to evaluate the effects of aerobic training on chemotherapy-related symptoms (nausea, vomiting, asthenia, and sensation of weakness), fatigue, mobility, clinical complications, and length of hospital stay in patients during the drug treatment cycle. Furthermore, we also aim to evaluate the adverse effects of aerobic training, patient satisfaction with the proposed intervention, its implementation, and its cost-effectiveness.

Our hypothesis is that aerobic training will decrease chemotherapy-related symptoms, fatigue, clinical complications, and length of hospital stay, in addition to not increasing mobility. In addition, we hypothesize that the proposed intervention will be cost-effective from the point of view of the patient and society due to the preservation of quality of life and lower health costs related to the treatment of adverse effects from chemotherapy.

Methods

Design

This is the protocol for a randomized controlled trial with 2 parallel groups, 1:1 allocation, and blind evaluation that will be conducted in the oncology ward of the Instituto de Assistência Médica ao Servidor State Public, São Paulo-SP, Brazil, in accord with the CONSORT (Consolidated Standards of Reporting Trials) checklist [12]. The trial has been registered on the Registro Brasileiro de Ensaios Clínicos (RBR-6b4zwx3).

Ethical Considerations

This study protocol was approved by the research ethics committees of the Universidade Cidade de São Paulo and Instituto de Assistência Médica ao Servidor (50436221.7.3001.5463). All participants will provide written informed consent before participating in this study. This will be collected and stored securely by one of the clinical data collection team members.

Participants

Patients older than 18 years diagnosed with cancer and hospitalized in the ward to undergo at least 1 cycle of chemotherapy will be eligible for this study. Patients will be included in the study if they do not have musculoskeletal, cognitive, or clinical limitations that interfere with the proposed assessments and interventions, such as heart disease (eg, moderate to severe aortic or pulmonary stenosis, decompensated heart failure, advanced cardiac arrhythmias, myocarditis, and unstable coronary insufficiency), lung diseases (eg, chronic obstructive pulmonary disease or decompensated asthma), diabetes mellitus, and decompensated systemic arterial hypertension with serum hemoglobin <8g/dL or hematocrit <25% or platelets <30,000 mm [5,13-15].

Patients who require transfer to the intensive care unit, or for whom chemotherapy treatment has been contraindicated or discontinued for any reason, will be excluded from the study.

Procedures

During the protocol period, all patients admitted to the oncology ward who are identified and meet the eligibility criteria will be invited to participate in the study by the evaluating physiotherapist. These eligible patients will be informed about the objectives of the study and invited to sign the informed consent form. Next, the patients will be evaluated regarding anthropometric and clinical characteristics, fatigue, and mobility, as well as the occurrence, frequency, intensity, and discomfort of the main adverse effects of chemotherapy. After the initial assessment, patients will be randomized into an intervention group, which will perform aerobic exercise sessions, and a control group, which will receive a booklet with guidelines (the same booklet will be given to the patients in the intervention group). The next day, the intervention will begin. Aerobic training will be carried out from Monday to Friday while the patients are hospitalized for the chemotherapy cycle in the oncology ward. Before carrying out the day’s aerobic exercise session, the patients will be asked if they feel any type of discomfort that is related to the previous day’s training (for example, muscle or joint pain in the lower limbs). If for any reason chemotherapy is interrupted for a patient, the exercises will also be interrupted, and as soon as chemotherapy treatment is resumed, the exercise will also be resumed. The booklet will be given to the patients and explained by a trained physiotherapist. Patients will be re-evaluated on the day following the last day of the chemotherapy cycle regarding the occurrence, frequency, intensity, and discomfort of adverse effects of the treatment, as well as fatigue, mobility, and satisfaction with the proposed intervention.

After the study intervention period, patients who need it will receive routine physiotherapeutic care provided by the physiotherapy team at the hospital. The incidence of clinical complications from chemotherapy and the length of hospital stay will be assessed as outcomes until hospital discharge. All data will be collected by a blinded assessor. Additionally, data will be coded and entered into a Microsoft Excel spreadsheet and will be double-checked before analysis. A visual representation of the study design is presented in Figure 1.

Figure 1 Clinical trial flowchart. BFI: Brief Fatigue Inventory; DEMMI: De Morton Mobility Index; MSAS-BR: Memorial Symptom Assessment Scale, Brazilian version.

Randomization

Immediately after baseline assessments and before starting the intervention, patients will be randomly allocated to 1 of 2 groups: intervention or control. The allocation will be conducted by a researcher who will not be involved in the selection or evaluation of patients or in the intervention; it will follow a randomization schedule generated by a website [16] with a 1:1 allocation rate. The rooms in the ward accommodate 2 to 4 patients (beds); therefore, randomization will be carried out by group or cluster [17]. The rooms will be randomized, because although the intervention is directed to one patient, it can affect another patient in the same room, contaminating those who should not receive the intervention and reducing the estimated result [17]. The researcher responsible for randomization will place a written document inside a sealed opaque envelope indicating which group (intervention or control) each room belongs to in order to ensure the confidential allocation of patients to the blinded evaluator [18]. Before starting the intervention, the physiotherapist responsible for the intervention will open the envelope in front of the patient and disclose which group the room the patient is in corresponds to.

Due to the nature of the study, it will not be possible to blind the physiotherapist responsible for the intervention or the patients. However, the evaluator will be blinded to the groups (intervention and control). After the intervention and assessments, the physiotherapist responsible for the intervention will ask the blinded evaluator to which group (intervention or control) he believes each patient belonged to evaluate the evaluator’s blinding.

Assessments

First of all, a standardized printed form will be used that will include personal data (name, age, sex, place of birth, contact telephone number, education, monthly family income, marital status, and occupation) and anthropometric data (height and weight, measured as recommended by the National Institute of Health, Heart, Lung, and Blood) [19]; diagnosis of current illness; preexisting illnesses; current or past smoking history; history of alcohol consumption and medications used; previous chemotherapy or radiotherapy; whether the current chemotherapy is neoadjuvant, adjuvant, treatment of choice, or palliative; and whether the patient is or was a practitioner of physical activity and how often they performed such activity.

The primary outcome will be assessed via frequency and intensity. Discomfort caused by the main adverse symptoms of chemotherapy (such as pain, nausea, and dry mouth) will be assessed using the Memorial Symptom Assessment Scale, Brazilian version (MSAS-BR) [20]. This scale consists of 32 symptoms that are scored by the patient according to their frequency and intensity (1-4 points, with 1 being less intense and frequent) and the discomfort (0-4, zero being no discomfort) that this symptom caused the previous week. This scale gives us a final index, which consists of the average of the 3 domains (frequency, severity, and bother) and all items, in addition to 4 subscales: Psych, which assesses psychological symptoms (with six items); Phys H, which assesses the most prevalent physical symptoms (with 12 items); Phys L, which assesses the less prevalent physical symptoms (with 14 items); and the Global Distress Index, which measures 4 psychological and 6 physical symptoms [20,21]. This scale will be applied in the initial and final assessments by an evaluator blind to which group the patient belongs.

Other outcomes will be assessed, such as fatigue, level of patient mobility, length of hospital stay, and clinical complications. Fatigue will be assessed using the Brief Fatigue Inventory, Brazilian version. This inventory consists of 9 items that are rated from 0 to 10 on a visual numeric scale. The first question is a dichotomous question about whether the patient has felt tired or fatigued in the last 7 days. Three items refer to the severity of fatigue at the time of assessment, the usual fatigue in the last 24 hours, and the worst fatigue in the last 24 hours, where 0 represents no fatigue and 10 “the worst fatigue imaginable.” The other 6 items refer to how fatigue interfered with different aspects of the patient’s life in the last 24 hours; these items are “general activities,” “mood,” “ability to walk,” “work” (including work outside and at home and daily tasks), “relationships with other people,” and “enjoying life,” where 0 means that it does not interfere and 10 means that it interferes completely [22,23]. This inventory will be applied in the initial and final assessments by an evaluator blind to which group the patient belongs.

The level of mobility will be assessed using the De Morton Mobility Index. This scale is made up of 15 activities, where 11 are classified as 0 or 1 (incapable or capable, respectively) and 4 are classified as 0, 1, or 2 (incapable, partial, and capable, respectively). Of the 15 activities, 3 are performed in bed, 3 in a chair, 4 involve static balance, 2 involve walking, and 3 involve dynamic balance. The scale was translated and validated in Brazilian Portuguese [24,25] and ranges from a score of 0, which represents low mobility, to 100, which represents high mobility. This index will be applied by an evaluator who is blind to which group the patient belongs and will be applied in the initial and final assessments.

In addition, the total number of days of hospital stay, possible clinical complications (cardiac, pulmonary, infectious, or neurological) arising from chemotherapy treatment, and the need for transfer to the intensive care unit will be accessed through the medical records of the patient.

The adverse effects of aerobic training, such as muscle pain, will be collected in the form of a question, developed by the researchers themselves, that will be answered every day before starting a new aerobic exercise session. In the same way, the patients’ subjective perception of satisfaction and discomfort in relation to the proposed protocol will be assessed through 2 questions developed by the researchers themselves that will be answered on the day of the patients’ final assessment. The patients’ responses to the questions will be on a scale of 0 to 10. In the question about satisfaction with the treatment, 0 will indicate “complete dissatisfaction” and 10 “maximum satisfaction.” When the question is about the discomfort of the treatment, 0 will indicate “no discomfort” and 10 will indicate “maximum discomfort.”

At the end of the treatment, the acceptability, suitability, and feasibility outcomes will be assessed using the Weiner scale [26], which was translated and adapted into Brazilian Portuguese [27]. The answer options for all questions are “completely disagree” (1 point), “disagree” (2 points), “neither agree nor disagree” (3 points), “agree” (4 points) and “completely agree” (5 points).

Acceptability is the perception among parties interested in implementing a given treatment that it is pleasant or satisfactory. It will be evaluated in terms of patient satisfaction in the intervention group according to their responses to the following statements: (1) “Physical exercise during chemotherapy treatment has my approval”; (2) “Physical exercise during chemotherapy treatment is attractive to me”; (3) “I enjoyed physical exercise during chemotherapy treatment”; and (4) “I recommend physical exercise during chemotherapy treatment.”

As for suitability, it is the relevance or compatibility of the proposed innovation (ie, treatment) for a given clinical practice environment. It will be evaluated by the following statements addressed to health professionals who care for patients included in this study, such as doctors, nurses, and physiotherapists: (1) “Physical exercise during chemotherapy treatment seems appropriate”; (2) “Physical exercise during chemotherapy treatment seems adequate”; (3) “Physical exercise during chemotherapy treatment seems applicable”; and (4) “Physical exercise during chemotherapy treatment seems to be a good option.”

Feasibility is defined as the extent to which a new treatment can be implemented within a given environment. It will be evaluated by the following statements addressed to physiotherapists and patients included in this study: (1) “Physical exercise during chemotherapy treatment seems implementable”; (2) “Physical exercise during chemotherapy treatment seems possible to perform”; (3) “Physical exercise during chemotherapy treatment seems feasible”; and (4) “Physical exercise during chemotherapy treatment seems easy to use.”

Economic evaluation will be monitored during the hospitalization period [28]. The index year will refer to the year of data collection. The costs of the intervention used will be assumed through the estimated value of the instruments used (oximeter and cycle ergometer), as well as the booklets and the in-hospital physiotherapy sessions (using the reference fees from the Physiotherapy Council table). The assessment of health care costs corresponds to the individual’s costs to the health care system and the costs of lost productivity due to total days of hospitalization. This assessment will be carried out using cost information obtained at the hospital. The cost-effectiveness analysis will be carried out by evaluating the effects of the intervention using the MSAS-BR-16 questionnaire, while the cost-utility analysis will be measured by quality-adjusted life years (QALYs) using the quality-of-life questionnaire EQ-5D-3L [29]. Sensitivity analysis will test uncertainty in key parameters, such as selection of cost weights and statistical variation in quality-of-life scores.

Interventions

The patients allocated to the intervention group will participate in an aerobic training protocol on a cycle ergometer during the period in which they are hospitalized and undergoing the chemotherapy cycle. The training will be carried out with daily sessions for 4 days lasting 40 minutes as long as the chemotherapy cycle continues. Exercise on the cycle ergometer will begin with a 5-minute warm-up and will progress to 30 minutes of exercise at a speed corresponding to 40%-60% of the heart rate reserve calculated by the Karvonen formula [30]: (220 – age) – (heart rate of rest × % intensity) + resting heart rate. The exercise will end with 5 minutes of recovery. The objective will be to maintain the patient at a score of 12 for the perception of dyspnea and physical fatigue, as measured by the Borg scale [31] (12 indicates that the patient’s dyspnea and physical fatigue is above “relatively easy” and below “slightly tiring”), during exercise on the cycle ergometer. The Borg scale presents a range of scores from 6 (no effort) to 20 (maximum effort). Therefore, if the patient is considered fit by the physiotherapist, the speed on the cycle ergometer will be gradually increased until the patient reaches 60% of the heart rate reserve. We will record heart rate and peripheral oxygen saturation (Palmsat 2500 pulse oximeter; Nonin), dyspnea and physical fatigue (Borg scale) [28], and blood pressure (Premium Aneroid Sphygmomanometer and Littmann Classic II Stethoscope) before, during, and after each physical training protocol session. The session may be interrupted at any time if the patient presents signs or symptoms such as dizziness, dyspnea, fatigue, or nausea. If the patient requires any emergency assistance during the period in which they are undergoing physical training supervised by the study physiotherapist, the same physiotherapist will contact the medical team on duty responsible for the patient in the oncology ward to provide the necessary assistance to stabilize the condition of the patient. To assist in blinding the evaluator, a booklet titled “Why do I need to move when I am hospitalized” [32] will be given to patients in both groups. The cycle ergometer will always be removed from the patient’s room after the training session to ensure blind evaluation.

The patients allocated in the control group will receive the same booklet (“Why do I need to move when I’m hospitalized”), which uses illustrations and short texts to encourage patients to spend more time in their chair, walk, and go up and down stairs (with a companion) [32]. This booklet will be delivered and explained by a trained physiotherapist and the participant will keep it for any questions and consultations.

Statistical Design

The calculation to determine the sample size was carried out based on a previous randomized clinical trial that also compared the effect of aerobic training compared to usual care on the deleterious effects of chemotherapy in patients with breast cancer [11]. Our study was designed to detect a difference of 2.7 (SD 4) points in the physical fatigue score, in addition to a difference of 6.2 (SD 7) episodes of vomiting or nausea between the groups. A power of 80%, an α of 5%, and a loss to follow-up of 15% of the sample were considered. A sample of 94 patients (47 patients in each group) was estimated.

After the data collection, all analyses will be conducted following intention-to-treat principles and will be performed by a researcher who will not be involved in the study assessments and intervention.

For analyzing the effect of the intervention, after a descriptive analysis and the Shapiro-Wilk normality test with a visual analysis, the groups will be compared using a linear mixed model for fatigue, mobility, and chemotherapy-related symptoms before and after the intervention. The length of hospital stay will also be compared between groups using Kaplan-Meier survival analysis. The χ2 test will be used to compare the clinical complication rates between groups. Descriptive analysis will be used for recruitment, completion, and adherence rates and potential adverse events. The significance level will be set at 5%. For all these analyses, SPSS (version 21.0; IBM Corp) will be used.

For economic evaluation, the analysis will be performed using chemotherapy-related symptoms, fatigue, and mobility as outcomes, and the cost-utility analysis will use QALYs. Missing data will be handled using multiple imputation by chained equations. Ten complete data sets will be created (efficiency loss <5%). Pooled estimates will be calculated according to the Rubin rules [33]. Average cost differences between groups will be calculated for total and disaggregated costs. Incremental cost-effectiveness and cost-utility rates will be calculated by dividing the difference in total costs by the difference in effects. Uncertainty surrounding cost differences and incremental cost-effectiveness and cost-utility ratios will be estimated using corrected and accelerated bootstrap techniques (5000 replications). The latter will be presented graphically in cost-effectiveness plans [34]. Cost-effectiveness acceptability curves will be estimated to indicate the probability of interventions being cost-effective compared to each other at different willingness-to-pay values [35]. Sensitivity analyses will be performed to assess the robustness of the results. The first sensitivity analysis will be performed from a health care perspective, and the second sensitivity analysis will be performed per protocol. The economic evaluation will be carried out using Stata (version 14; StataCorp).

Results

In March 2023, the clinical trial registration was approved. Recruitment and data collection for the trial is ongoing, and the results of this study are likely to be published in late 2025.

Discussion

Anticipated Findings

To our knowledge, this will be the first controlled trial with an economic analysis that will be carried out to test the acute effects of aerobic exercise in patients undergoing a cycle of chemotherapy. However, based on previous studies conducted in the outpatient phase of cancer treatment [36], we believe that aerobic training will be cost-effective and will lead to a lower incidence of adverse effects from chemotherapy treatment, less fatigue, maintenance of mobility, shorter hospital stays, and lower incidence of clinical complications when compared to the control group.

Despite the potential beneficial effects of physical exercise for patients with cancer, a decline in activity level has been reported in this population [37]. This decline appears to have an impact on quality of life and to lower performance in activities of daily living in women with breast cancer. A possible hypothesis for this decrease in physical exercise may be the relationship with psychosocial barriers in these patients [37].

Smith and colleagues [38] conducted a study that aimed to assess exercise behavior, barriers, facilitators, and motivators for exercise participation and the different exercise support needs of cancer survivors living in a rural Canadian community. They observed that the main barriers reported were cost, time, distance, transportation, and side effects. Still, the study described above was able to observe that patients reported that access to a gym, equipment, social support, transportation, and information on physical exercise were facilitators [38].

The Clinical Oncology Society of Australia and Exercise and Sport Science Australia encourage health care professionals who work with patients with cancer to seek to know more about the relationship between physical activity and cancer and understand how they must guide their patients to practice physical activity [39]. They also advise health professionals to refer patients to professionals who are more prepared and who better understand the practice of exercise in patients with cancer.

In the study by Park and colleagues [40], the authors analyzed the influence of doctors on their patients among 162 people who overcame early-stage breast and colorectal cancer and who completed primary and adjuvant treatment. Only 80.7% (n=130) of participants in the study remained until the end. Three groups were stratified: the first was the control group (n=59); the second group received exercise recommendations from oncologists (n=53); and the third group received physical activity recommendations from oncologists and an exercise motivation package (n=50). Participants were assessed at the beginning of the study and after 4 weeks [40].

The motivation package provided exercise DVDs, a pedometer, an exercise diary, and a 15-minute physical education session. In the recommendations, the oncologists said, “Studies have shown that engaging in moderate PA [physical activity] more than 150 minutes per week could significantly reduce the recurrence of breast and colorectal cancer. Therefore, it is highly recommended that breast and colorectal cancer survivors participate in at least 150 minutes of moderate-level PA and twice-weekly strengthening exercises” [40].

We have seen in the current literature the importance of understanding how much physical exercise can impact the treatment and quality of life of patients with cancer undergoing chemotherapy treatment. Studies have shown that incorporating adequate and supervised exercise can help combat fatigue, improve physical fitness, reduce anxiety and depression, and help maintain functionality. However, it is important that the exercise program is individualized, taking into account the stage of the disease, as well as the patient’s age, needs, and limitations. Supervision by specialized professionals is essential to ensure safety and effectiveness. In summary, physical exercise can be a valuable tool in managing symptoms and promoting well-being in patients with cancer, complementing conventional treatments and providing both physical and emotional improvements during the cancer treatment journey.

Conclusion

Chemotherapy has side effects that negatively impact the quality of life of patients with cancer. Aerobic exercise can reduce these side effects in a simple and inexpensive way. Oncology could be a way to expand the field of work for physical therapists if the intervention works.

The São Paulo Research Foundation (FAPESP) sponsors ACL (grant 2023/07735-8). The Brazilian Federal Agency for Support and Evaluation of Graduate Education (CAPES) sponsors WdLS. The study funders (FAPESP and CAPES) are public research foundations and do not have any influence on the study’s results, including data collection; the management, analysis, and interpretation of data; or writing of the manuscript.

Multimedia Appendix 1 Peer review reports from the Pró-Reitoria de Pós-Graduação, Pesquisa e Extensão (PRPGPE) - Universidade Cidade de São Paulo (UNICID) - São Paulo Research Foundation (FAPESP) (Brazil).

Abbreviations

CONSORT Consolidated Standards of Reporting Trials

MSAS-BR Memorial Symptom Assessment Scale

QALY quality-adjusted life year

Data Availability

The data obtained in this study will be available from the corresponding author (ACL) upon reasonable request.

Conflicts of Interest: None declared.
==== Refs
1 Santos MDO Lima FCDSD Martins LFL Oliveira JFP Almeida LMD Cancela MDC Estimativa de incidência de câncer no Brasil, 2023-2025 Rev Bras Cancerol 2023 02 06 69 1 e-213700 10.32635/2176-9745.rbc.2023v69n1.3700
2 SMJ ABC do câncer: abordagens básicas para o controle do câncer 2024-08-03 https://www.inca.gov.br/publicacoes/livros/abc-do-cancer-abordagens-basicas-para-o-controle-do-cancer
3 Sohi GK Levy J Delibasic V Davis LE Mahar AL Amirazodi E Earle CC Hallet J Hammad A Shah R Mittmann N Coburn NG The cost of chemotherapy administration: a systematic review and meta-analysis Eur J Health Econ 2021 06 22 4 605 620 10.1007/s10198-021-01278-0 33687618 10.1007/s10198-021-01278-0 33687618
4 Gastos com os câncers no Brasil Silva INdCJAGd 2024-08-03 https://www.inca.gov.br/publicacoes/relatorios/gastos-federais-atuais-e-futuros-com-os-canceres-atribuiveis-aos-fatores-de
5 Mijwel S Bolam K Gerrevall J Foukakis T Wengström Yvonne Rundqvist H Effects of exercise on chemotherapy completion and hospitalization rates: the OptiTrain breast cancer trial Oncologist 2020 01 25 1 23 32 10.1634/theoncologist.2019-0262 31391297 theoncologist.2019-0262 31391297
6 Wengström Y Bolam KA Mijwel S Sundberg CJ Backman M Browall M Norrbom J Rundqvist H Optitrain: a randomised controlled exercise trial for women with breast cancer undergoing chemotherapy BMC Cancer 2017 02 06 17 1 100 10.1186/s12885-017-3079-x 28166765 10.1186/s12885-017-3079-x 28166765
7 Travier N Velthuis MJ Steins Bisschop CN van den Buijs B Monninkhof EM Backx F Los M Erdkamp F Bloemendal HJ Rodenhuis C de Roos MA Verhaar M ten Bokkel Huinink D van der Wall E Peeters PH May AM Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial BMC Med 2015 06 08 13 1 121 10.1186/s12916-015-0362-z 26050790 10.1186/s12916-015-0362-z 26050790
8 Carayol M Ninot G Senesse P Bleuse J Gourgou S Sancho-Garnier H Sari C Romieu I Romieu G Jacot W Short- and long-term impact of adapted physical activity and diet counseling during adjuvant breast cancer therapy: the "APAD1" randomized controlled trial BMC Cancer 2019 07 25 19 1 737 10.1186/s12885-019-5896-6 31345179 10.1186/s12885-019-5896-6 31345179
9 Courneya K Segal R Mackey J Gelmon K Reid R Friedenreich C Ladha Ab Proulx C Vallance Jk Lane K Yasui Y McKenzie Dc Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial J Clin Oncol 2007 10 01 25 28 4396 404 10.1200/JCO.2006.08.2024 17785708 JCO.2006.08.2024 17785708
10 Courneya K McKenzie D Mackey J Gelmon K Friedenreich C Yasui Y Reid Robert D Cook Diane Jespersen Diana Proulx Carolyn Dolan Lianne B Forbes Cynthia C Wooding Evyanne Trinh Linda Segal Roanne J Effects of exercise dose and type during breast cancer chemotherapy: multicenter randomized trial J Natl Cancer Inst 2013 12 04 105 23 1821 32 10.1093/jnci/djt297 24151326 djt297 24151326
11 van Waart H Stuiver M van Harten Wh Geleijn E Kieffer J Buffart L de Maaker-Berkhof M Boven E Schrama J Geenen Mm Meerum Terwogt Jm van Bochove A Lustig V van den Heiligenberg Sm Smorenburg Ch Hellendoorn-van Vreeswijk Ja Sonke Gs Aaronson Nk Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial J Clin Oncol 2015 06 10 33 17 1918 27 10.1200/JCO.2014.59.1081 25918291 JCO.2014.59.1081 25918291
12 Mitchell-Box K Braun KL Fathers' thoughts on breastfeeding and implications for a theory-based intervention J Obstet Gynecol Neonatal Nurs 2012 41 6 E41 50 10.1111/j.1552-6909.2012.01399.x 22861175 S0884-2175(15)31215-6
13 Kimura AARB Rodrigues CCV Pinto CA Brito CMM Cuidados em pacientes citopênicos Manual de Reabilitação em Oncologia do ICESP 2014 Sao Paulo, Brazil Editora Manole 1 722
14 Rezende L Campanholi LL Tessaro A Citopenia Manual de Condutas e Práticas Fisioterapêuticas em Onco-hematologia da ABFO 2018 Sao Paulo, Brazil Ed Thieme Revinter 1 192
15 Ferrari IS Lino V Fisioterapia no transplante de células-tronco hematopoiéticas Oncologia Para Fisioterapeutas 2020 Sao Paulo, Brazil Editora Manole 1 392
16 Randomisation and online databases for clinical trials Sealed Envelope 2024-07-25 http://www.sealedenvelope.com
17 Edwards SJL Braunholtz DA Lilford RJ Stevens AJ Ethical issues in the design and conduct of cluster randomised controlled trials BMJ 1999 05 22 318 7195 1407 9 10.1136/bmj.318.7195.1407 10334756 10334756
18 Schulz KF Chalmers I Hayes R J Altman D G Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials JAMA 1995 02 01 273 5 408 12 10.1001/jama.273.5.408 7823387 7823387
19 Xavier Pi-Sunyer F Becker DM Bouchard C Carleton R Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report 1998 Washington, DC National Heart, Lung, and Blood Institute 51S 209S
20 da Rocha L Carvalho MDS Moraes de Lacerda AA Vizeu Viana Áila F Ramos RDS Guimarães RM Equivalência semântica da versão em português do instrumento Memorial Symptom Assessment Scale (MSAS) para avaliar sintomas em pacientes oncológicos Rev Bras Pesq Saúde 2018 1 31 19 2 83 91 10.21722/RBPS.V19I2.20584
21 Menezes JRD Luvisaro BMO Rodrigues CF Muzi CD Guimarães Raphael Mendonça Test-retest reliability of Brazilian version of Memorial Symptom Assessment Scale for assessing symptoms in cancer patients Einstein (Sao Paulo) 2017 15 2 148 154 10.1590/S1679-45082017AO3645 28767911 S1679-45082017000200148 28767911
22 Mendoza TR Wang XS Cleeland CS Morrissey M Johnson BA Wendt JK Huber SL The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory Cancer 1999 03 01 85 5 1186 96 10.1002/(sici)1097-0142(19990301)85:5<1186::aid-cncr24>3.0.co;2-n 10091805 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N 10091805
23 Nunes AF Bezerra CO Custódio Jaqueline Dos Santos Friedrich CF Oliveira ISD Lunardi AC Clinimetric properties of the Brief Fatigue Inventory applied to oncological patients hospitalized for chemotherapy J Pain Symptom Manage 2019 02 57 2 297 303 10.1016/j.jpainsymman.2018.10.508 30391653 S0885-3924(18)31055-8 30391653
24 de Morton NA Davidson M Keating JL Validity, responsiveness and the minimal clinically important difference for the de Morton Mobility Index (DEMMI) in an older acute medical population BMC Geriatr 2010 09 30 10 1 72 10.1186/1471-2318-10-72 20920285 1471-2318-10-72 20920285
25 Tavares LS Moreno NA de Aquino BG Costa LF Giacomassi IWS Simões Maria do Socorro Morais Pereira Lunardi AC Reliability, validity, interpretability and responsiveness of the DEMMI mobility index for Brazilian older hospitalized patients PLoS One 2020 15 3 e0230047 10.1371/journal.pone.0230047 32187212 PONE-D-19-13537 32187212
26 Weiner BJ Lewis CC Stanick C Powell BJ Dorsey CN Clary AS Boynton MH Halko H Psychometric assessment of three newly developed implementation outcome measures Implement Sci 2017 08 29 12 1 108 10.1186/s13012-017-0635-3 28851459 10.1186/s13012-017-0635-3 28851459
27 Fioratti I Santos VS Fernandes LG Rodrigues KA Soares RJ Saragiotto BT Translation, cross-cultural adaptation and measurement properties of three implementation measures into Brazilian-Portuguese Arch Physiother 2023 03 27 13 1 7 10.1186/s40945-023-00160-x 36967380 10.1186/s40945-023-00160-x 36967380
28 Miyamoto GC Franco KFM van Dongen JM Franco YRDS de Oliveira NTB Amaral DDV Branco ANC da Silva ML van Tulder MW Cabral CMN Different doses of Pilates-based exercise therapy for chronic low back pain: a randomised controlled trial with economic evaluation Br J Sports Med 2018 07 52 13 859 868 10.1136/bjsports-2017-098825 29525763 bjsports-2017-098825 29525763
29 Bagattini ?M Camey SA Miguel SR Andrade MV de Souza Noronha KVM de C Teixeira Monica Akissue Lima AF Santos M Polanczyk CA Cruz LN Electronic version of the EQ-5D Quality-of-Life Questionnaire: adaptation to a Brazilian population sample Value Health Reg Issues 2018 12 17 88 93 10.1016/j.vhri.2017.11.002 29754016 S2212-1099(18)30048-7 29754016
30 Glen TM Princípios do exercício aeróbico Exercícios Terapêuticos: Fundamentos e Técnicas 2021 Sao Paulo, Brazil Editora Manole
31 Borg GA Psychophysical bases of perceived exertion Med Sci Sports Exerc 1982 14 5 377 81 7154893 7154893
32 Moreno NA de Aquino BG Garcia IF Tavares LS Costa LF Giacomassi IWS Lunardi AC Physiotherapist advice to older inpatients about the importance of staying physically active during hospitalisation reduces sedentary time, increases daily steps and preserves mobility: a randomised trial J Physiother 2019 10 65 4 208 214 10.1016/j.jphys.2019.08.006 31521553 S1836-9553(19)30093-1 31521553
33 Sterne JAC White IR Carlin JB Spratt M Royston P Kenward MG Wood AM Carpenter JR Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls BMJ 2009 06 29 338 1 b2393 10.1136/bmj.b2393 19564179 bmj.b2393 19564179
34 Willan AR Briggs AH Hoch JS Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data Health Econ 2004 05 13 5 461 75 10.1002/hec.843 15127426 15127426
35 Black WC The CE plane: a graphic representation of cost-effectiveness Med Decis Making 1990 10 3 212 4 10.1177/0272989X9001000308 2115096 2115096
36 Dennett AM Tang CY Chiu A Osadnik C Granger CL Taylor NF Campbell KL Barton C A cancer exercise toolkit developed using co-design: mixed methods study JMIR Cancer 2022 04 21 8 2 e34903 10.2196/34903 35451966 v8i2e34903 35451966
37 Yildiz Kabak V Gursen C Aytar A Akbayrak T Duger T Physical activity level, exercise behavior, barriers, and preferences of patients with breast cancer-related lymphedema Support Care Cancer 2021 07 29 7 3593 3602 10.1007/s00520-020-05858-3 33170403 10.1007/s00520-020-05858-3 33170403
38 Smith TG Troeschel AN Castro KM Arora NK Stein K Lipscomb J Brawley OW McCabe RM Clauser SB Ward E Perceptions of patients with breast and colon cancer of the management of cancer-related pain, fatigue, and emotional distress in community oncology J Clin Oncol 2019 07 01 37 19 1666 1676 10.1200/JCO.18.01579 31100037 31100037
39 Alderman G Semple S Cesnik R Toohey K Health care professionals' knowledge and attitudes toward physical activity in cancer patients: a systematic review Semin Oncol Nurs 2020 10 36 5 151070 10.1016/j.soncn.2020.151070 33010981 S0749-2081(20)30085-1 33010981
40 Park J Lee J Oh M Park H Chae J Kim D Lee Mi Kyung Yoon Yong Jin Lee Chul Won Park Seho Jones Lee W Kim Nam Kyu Kim Seung Il Jeon Justin Y The effect of oncologists' exercise recommendations on the level of exercise and quality of life in survivors of breast and colorectal cancer: A randomized controlled trial Cancer 2015 08 15 121 16 2740 8 10.1002/cncr.29400 25965782 25965782
